Skip to content
Drug Policy Watch™
LatestTracking drug policy in all 50 states and Congress, updated every morning.See all ›
Drug Policy Watch · State Brief 2026

Vermont

Snapshot (structured)

Adult-use cannabis
Legal. Possession legalized 2018 (Act 86); regulated retail sales legalized 2020 (Act 164, S.54), retail stores opened October 2022.
Medical cannabis
Legal since 2004; program now folded under the Cannabis Control Board.
Home grow
Legal for adults 21+, up to 2 mature and 4 immature plants per dwelling.
Intoxicating hemp / hemp THC
Restricted. Intoxicating hemp cannabinoids (Delta-8, Delta-10, THCA, HHC, etc.) are barred from the hemp retail channel and routed to the licensed cannabis system; a separate low-dose consumable hemp lane (10 mg/serving, 40 mg/package, 21+) was created in 2025.
Psychedelics
Not decriminalized. State convened a Psychedelic Therapy Advisory Working Group (created by 2023's S.114), which reported in late 2024; no therapeutic-access program enacted as of 2026.
Broad decriminalization
No. Prior all-drug decriminalization bills (H.423, S.119, S.300) did not become law; a 2024 personal-use-amount bill was vetoed by Gov. Scott.
Harm reduction
Strong. Syringe services, broad naloxone access, fentanyl and xylazine test strips, and statutory authorization for overdose prevention centers (2024 veto override); Burlington site in development.
Governor (party)
Phil Scott (Republican).
Legislature control
Democratic (with Progressive allies) in both chambers.
Citizen ballot initiatives allowed
No. Vermont has no statewide citizen initiative or referendum process.
Enclosure pressure score
2/5

Cannabis

Adult-use cannabis is legal. Vermont first legalized possession and home cultivation in 2018 (Act 86), becoming the first state to legalize through the legislature rather than a ballot measure. It legalized a regulated, taxed retail market in 2020 via Act 164 (S.54), and licensed adult-use stores opened in October 2022. (https://www.mpp.org/states/vermont/)

Medical cannabis has been legal since 2004; the program and the adult-use market are both overseen by the Cannabis Control Board (CCB). Home grow is permitted for adults 21 and older, capped at 2 mature and 4 immature plants per dwelling. (https://www.mpp.org/states/vermont/)

Market structure deliberately favors small operators to limit consolidation. Cultivation is tiered by canopy size, with the smallest outdoor Tier 1 (up to 1,000 sq ft canopy or fewer than 125 plants) carrying reduced fees and lighter application requirements. Annual cultivation fees scale from $750 (outdoor Tier 1) up to roughly $34,000 (outdoor Tier 6) and from $1,500 (indoor Tier 1) up to $75,000 (indoor Tier 6); mixed-cultivation fees run from about $2,250 to $19,500. (https://vermontcannabissolutions.com/wp-content/uploads/sites/29/2022/04/Fee-Bill-as-passed-by-House.pdf, https://canndelta.com/us/vermont/) In November 2023 the CCB temporarily paused new licensing for the largest cultivators (Tier 4 and Tier 5) over oversupply concerns in Vermont's small market. (https://cannabispromotions.com/regulations/states/vermont)

Taxes: a 14% cannabis excise tax plus the 6% state sales tax, and an optional 1% local option tax. (https://tax.vermont.gov/business/cannabis-excise-tax, https://www.salestaxhandbook.com/vermont/marijuana) Vermont law currently imposes a 30% THC cap on flower and a 60% cap on solid concentrates. (https://legislature.vermont.gov/Documents/2026/Docs/BILLS/S-0278/S-0278%20As%20passed%20by%20the%20Senate%20Official.pdf)

Key 2026 action: S.278 (Sen. Kesha Ram Hinsdale) would, as introduced, raise the retail transaction limit from 1 to 2 ounces, remove the THC potency caps, cut the excise tax from 14% to 10%, and authorize delivery and cannabis events. The Senate passed it and sent it to the House on April 1, 2026; the House then stripped the potency-cap removal, the tax cut, and delivery authorization after public-health testimony. S.278 was signed into law in June 2026, with core provisions effective July 1, 2026: the 2-ounce possession and purchase limit, authorization for interstate-commerce agreements, and cannabis events. The enacted law is narrower than the bill as introduced; the potency-cap removal, the excise-tax cut, and delivery authorization were not included. (https://themarijuanaherald.com/2026/03/vermont-senate-committee-approves-bill-to-cut-marijuana-tax-double-purchase-limits-and-allow-events-and-deliveries/, https://www.compassvermont.com/p/vermont-house-committee-drops-plan, https://marijuanaandthelaw.com/vermont-s278-cannabis-bill-explained/)

Hemp

Vermont takes a strict stance on intoxicating hemp. The state does not follow the federal "0.3% Delta-9" loophole; legality turns on intoxicating potential, not just Delta-9 concentration. As of 2026, Delta-8, Delta-10, THCA, HHC, THCP, THCB and similar cannabinoids are restricted from hemp retail sale and may only move through licensed cannabis dispensaries (if at all). The CCB had already banned Delta-8 by administrative rule. (https://burningdaily.com/blogs/learn/vermont-cannabis-hemp-laws)

2025 state action: Act 56 (June 2025) clarified law-enforcement authority to seize illegal cannabis products, including synthetic cannabinoids such as Delta-8. Separately, 2025 legislation created a parallel consumable-hemp licensing lane administered through the alcohol/beverage control system with stricter limits: 10 mg THC per serving, 40 mg per package, 21+. (https://burningdaily.com/blogs/learn/vermont-cannabis-hemp-laws) The Senate Agriculture Committee was working on further hemp regulation in early 2026 (testimony of CCB chair James Pepper, Jan. 8, 2026). (https://legislature.vermont.gov/Documents/2026/Workgroups/Senate%20Agriculture/Cannabis/W~James%20Pepper~Hemp%20Regulation~1-8-2026.pdf)

Federal exposure and the November 12, 2026 deadline: On November 12, 2025, federal appropriations legislation (Section 781 of the FY2026 Appropriations Act) redefined hemp to a total-THC standard (0.3% total THC dry weight, inclusive of THCA and Delta-8) and capped final-form hemp products at 0.4 mg total THC per container, effective November 12, 2026. Industry groups estimate roughly 95% of current hemp-derived cannabinoid products would become noncompliant. (https://www.arnoldporter.com/en/perspectives/advisories/2025/12/major-changes-to-federal-regulation-of-hemp-derived-products, https://www.congress.gov/crs-product/IN12620) Because Vermont already channels intoxicating cannabinoids into its licensed cannabis market, the federal change largely reinforces existing state policy rather than upending it; the main local effect would be on any remaining low-dose consumable-hemp products that exceed the new 0.4 mg per-container federal cap. As of the searches here, the 2026 Farm Bill markup (House Agriculture Committee, March 5, 2026, advanced 34-17) left the intoxicating-hemp ban intact, while a competing Senate bill (Cannabinoid Safety and Regulation Act, Wyden/Merkley, Dec. 2025) would replace it with a regulatory framework. (https://www.cannabisbusinesstimes.com/hemp/news/15823852/s-house-passes-2026-farm-bill-intoxicating-hemp-product-ban-remains)

Psychedelics

Vermont has not decriminalized psychedelics and has no operating therapeutic-access program. In 2023, S.114 created a Psychedelic Therapy Advisory Working Group to study psilocybin and MDMA and recommend whether the state should allow provider-administered psychedelic therapy; an earlier psilocybin-legalization provision was stripped in committee at the urging of Sen. Ginny Lyons (D), who argued decriminalization could complicate a therapeutic approach. The working group reported its findings to the legislature (report dated late 2024). (https://www.marijuanamoment.net/vermont-senate-panel-scales-back-psilocybin-legalization-bill-pivoting-focus-to-working-group-on-psychedelic-assisted-therapy/, https://legislature.vermont.gov/assets/Legislative-Reports/The-Psychedelic-Therapy-Advisory-Working-Group_Final-Report.pdf)

2026 bills: A specific 2026 psychedelics bill could not be confirmed in these searches; prior psilocybin-legalization and psychedelic-decriminalization measures date to the 2023-2024 sessions. Whether a follow-on bill responding to the working group's report has been introduced in 2026 is unconfirmed; check the live trackers below. (https://www.marijuanamoment.net/vermont-lawmakers-file-bills-to-legalize-psychedelics-and-decriminalize-all-drugs/)

Broader drug policy

Decriminalization of drugs beyond cannabis has not passed. Reform advocates filed an all-drug decriminalization package in the 2023-2024 window: H.423 (Reps. Logan Nicoll (D) and Taylor Small (P/D), with 47 co-sponsors) and a Senate companion S.119 (Sen. Tanya Vyhovsky (P/D) and others) would have made simple possession of a "personal use supply" a $50 civil offense waivable through substance-use screening. (https://www.marijuanamoment.net/vermont-lawmakers-file-bills-to-legalize-psychedelics-and-decriminalize-all-drugs/) Sen. Vyhovsky's 2024 bill S.300 included eliminating criminal penalties for small personal-use possession; Gov. Scott vetoed a 2024 bill that would have set personal-use amounts to reduce criminalization. (https://www.marijuanamoment.net/vermont-governor-vetoes-bill-on-reducing-the-criminalization-of-drugs-by-setting-personal-use-amounts/) Whether these are reintroduced in the 2026 session is unconfirmed here.

Harm reduction is comparatively strong. Vermont operates syringe services, broad naloxone distribution, and recommends fentanyl and xylazine test strips. (https://www.healthvermont.gov/sites/default/files/document/dsu-overdose-prevention-centers.pdf) In spring 2024, the legislature overrode Gov. Scott's veto to authorize overdose prevention centers (supervised consumption), allocating about $1.1 million from opioid-settlement funds for a Burlington pilot. (https://vtdigger.org/2024/05/07/final-reading-lawmakers-send-safe-injection-site-pilot-legislation-to-gov-phil-scott/) As of 2025-2026, Burlington (Mayor Emma Mulvaney-Stanak) is standing up that center; the city appointed Theresa Vezina as special assistant for implementation and is selecting a service provider. (https://www.wcax.com/2025/01/08/plans-move-forward-burlington-safe-injection-site/, https://www.vermontpublic.org/show/vermont-edition/2025-03-10/what-we-know-so-far-about-burlingtons-overdose-prevention-center-plans) Howard Center's Safe Recovery program in Burlington provides walk-in harm-reduction services. (https://howardcenter.org/substance-use-recovery/harm-reduction/)

Sentencing and expungement for cannabis are addressed below under Equity and expungement.

Political landscape

Governor: Phil Scott (Republican), generally cautious on drug-policy expansion (vetoed overdose prevention centers, later overridden; vetoed a personal-use-amounts drug bill). (https://www.marijuanamoment.net/vermont-governor-vetoes-bill-on-reducing-the-criminalization-of-drugs-by-setting-personal-use-amounts/, https://vtdigger.org/2024/05/07/final-reading-lawmakers-send-safe-injection-site-pilot-legislation-to-gov-phil-scott/)

Chamber control (for the 2026 session): Senate Democrats hold roughly 16-13 with one Progressive (about 17-13 effective) in the 30-seat chamber; House Democrats hold about 87-56 with four Progressives and three independents (about 94-56 effective) in the 150-seat chamber. This is a divided government with a Democratic/Progressive-led legislature and a Republican governor. (https://ballotpedia.org/2026_Vermont_legislative_session)

Key committees: cannabis policy runs through the Senate Committee on Economic Development, Housing and General Affairs and the corresponding House General and Housing committee; hemp through Senate Agriculture; psychedelics/therapeutic access through Senate Health and Welfare. (https://legislature.vermont.gov/)

Named reform champions: Sen. Kesha Ram Hinsdale (D) (lead on cannabis-market bill S.278); Sen. Tanya Vyhovsky (P/D) and Reps. Logan Nicoll (D) and Taylor Small (P/D) (drug decriminalization). Sen. Ginny Lyons (D) has shaped the psychedelics approach toward therapeutic use over decriminalization. (https://www.marijuanamoment.net/vermont-lawmakers-file-bills-to-legalize-psychedelics-and-decriminalize-all-drugs/, https://www.marijuanamoment.net/vermont-senate-panel-scales-back-psilocybin-legalization-bill-pivoting-focus-to-working-group-on-psychedelic-assisted-therapy/) Named opponents: Gov. Scott has been the principal brake on broader decriminalization and supervised consumption. Other named opponents are unconfirmed.

Ballot initiatives

Vermont does not have a statewide citizen initiative or referendum process; drug-policy change happens through the legislature. There are therefore no pending statewide citizen ballot measures on cannabis, hemp, psychedelics, or drug decriminalization. (https://ballotpedia.org/Vermont_State_Legislature)

Equity and expungement

Vermont built automatic expungement into its decriminalization framework. Cannabis-possession convictions for 2 ounces or less entered before January 1, 2021 were automatically expunged by January 1, 2022, and the law also reached possession of up to 4 mature or 8 immature plants. People with simple-possession records may deny them on employment, licensing, and civil-rights applications and are treated as if never arrested or convicted. (https://norml.org/blog/2020/09/22/vermont-lawmakers-send-marijuana-retail-sales-bill-automatic-expungement-measure-to-governors-desk/, https://www.mpp.org/states/vermont/vermont-cannabis-expungement-and-penalty-reduction-summary/)

Social-equity licensing: the CCB provides priority licensing and fee reductions for individuals with prior cannabis convictions and residents of communities disproportionately affected by enforcement. (https://cannabispromotions.com/regulations/states/vermont) Who is excluded: the automatic expungement was capped at 2 ounces, so higher-weight or sale-related convictions are not automatically cleared; those generally require petition-based relief.

Market and barriers

Tax: 14% cannabis excise tax, 6% state sales tax, optional 1% local tax. (https://tax.vermont.gov/business/cannabis-excise-tax) License/cultivation fees: annual cultivation fees range from $750 (outdoor Tier 1) to about $34,000 (outdoor Tier 6) and $1,500 to $75,000 indoor; mixed cultivation roughly $2,250 to $19,500. (https://vermontcannabissolutions.com/wp-content/uploads/sites/29/2022/04/Fee-Bill-as-passed-by-House.pdf) Caps: temporary pause on new Tier 4/Tier 5 cultivation licenses (since Nov 2023) to manage oversupply. (https://cannabispromotions.com/regulations/states/vermont) Licensees: the CCB has licensed 70+ retail dispensaries and hundreds of cultivators across tiers; precise current counts are unconfirmed (check the CCB). (https://cannabispromotions.com/regulations/states/vermont) Capital/residency requirements specific to applicants were not confirmed in this research and should be checked against current CCB rules. (https://ccb.vermont.gov/sites/ccb/files/2022-02/Final%20Proposed%20Rule%201%20-%20Licensing%20of%20Cannabis%20Establishments.pdf)

Enclosure read

Vermont is one of the more open, anti-consolidation cannabis regimes in the country. The license structure intentionally favors small and outdoor cultivators with low entry fees, the largest-tier licenses are paused to protect smaller growers from oversupply, social-equity priority and fee waivers are built in, and expungement was automatic for the most common low-level offenses. Home grow is legal. These features fence out very few small operators. The pressures pushing toward enclosure are mostly external and indirect: the high effective tax stack (14% excise plus sales tax) squeezes margins; S.278's market-competitiveness push hints at consolidation pressure from neighboring states; and the federal hemp redefinition (Nov 12, 2026) will shut down the lightly regulated hemp-THC side channel, steering consumers into the licensed cannabis market (a centralizing effect, though arguably a closing of a separate loophole rather than enclosure of the cannabis commons itself). On balance the state is closer to open than fenced, hence a score of 2/5.

Enclosure pressure score: 2/5.

What to watch next

Regulators

Federal exposure (2026)

Rescheduling and 280E. Cannabis remains Schedule I by default under federal law. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III; recreational (adult-use) cannabis stays Schedule I. The broader DEA rescheduling hearing opened June 29, 2026, and may slip to 2027. Practical effect for Vermont: the medical program, which is folded under the Cannabis Control Board, gains relief from IRS Section 280E (which currently bars ordinary business deductions for sellers of Schedule I and II substances), while the adult-use retail market that opened in October 2022 does not. Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not cover state recreational businesses. So Vermont's adult-use cultivators and retailers keep paying federal tax on gross revenue with deductions disallowed, a burden that falls hardest on thin-margin operators. That matters more here than in most states because Vermont deliberately built a small-grower-friendly tiered market: the smallest outdoor Tier 1 growers (up to 1,000 sq ft canopy or fewer than 125 plants) and the social-equity licensees the state recruits are precisely the operators least able to absorb a non-deductible federal tax bill. Federal medicalize-and-control rescheduling rewards FDA-track pharmaceutical players and, at the margin, vertically integrated medical operators, not Vermont's intentionally fragmented adult-use base. (https://www.arnoldporter.com/en/perspectives/advisories/2025/12/major-changes-to-federal-regulation-of-hemp-derived-products)

The November 12, 2026 hemp cliff. FY2026 agriculture appropriations (Section 781, sponsor Rep. Andy Harris, R-MD) narrowed the federal definition of hemp to a total-THC standard (roughly 0.4 mg THC per container), recriminalizing an estimated 90 to 95 percent of intoxicating hemp products effective November 12, 2026. The H.R.7010 delay was not enacted, and the 2026 Farm Bill (H.R.7567) keeps the ban. For Vermont the federal cliff mostly reinforces existing state policy rather than upending it, because Vermont already bars intoxicating hemp cannabinoids (Delta-8, Delta-10, THCA, HHC, THCP, and similar) from the hemp retail channel and routes them to the licensed cannabis system. The practical effect is narrow: Vermont's separate low-dose consumable-hemp lane created in 2025 (10 mg THC per serving, 40 mg per package, 21+, administered through the alcohol/beverage control system) sits well above the new 0.4 mg per-container federal cap, so those products would become federally noncompliant on November 12, 2026 even though they are legal under Vermont law. That state-federal mismatch is the live exposure to watch; the broader intoxicating-hemp market the federal ban targets is already closed in Vermont. (https://www.congress.gov/crs-product/IN12620, https://burningdaily.com/blogs/learn/vermont-cannabis-hemp-laws)

Banking. SAFER Banking has stalled in a Republican Congress. Because cannabis is still Schedule I federally, most banks and credit unions decline to serve cannabis businesses or charge steep compliance fees, forcing many operators to run cash-heavy. This federal lever bears down hardest on exactly the actors Vermont set out to protect. A large multistate operator can absorb cash-handling costs, premium banking fees, and the 280E tax hit; a Tier 1 outdoor craft grower or a social-equity licensee operating on a few thousand dollars of margin cannot. Lack of normal banking and lending also blocks the small-loan and working-capital access that small growers need to survive a bad season or oversupply, the same oversupply that already prompted the CCB to pause new Tier 4 and Tier 5 licenses in November 2023. So the federal banking gap quietly pushes Vermont's market toward the consolidation the state's license design was built to prevent. (https://www.mpp.org/states/vermont/, https://cannabispromotions.com/regulations/states/vermont)

Psychedelics. Psilocybin, MDMA, and ibogaine remain Schedule I federally. The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review, but there is no federal approval yet. Vermont is at the study-group stage: S.114 (2023) created the Psychedelic Therapy Advisory Working Group, which reported in late 2024, and no therapeutic-access program has been enacted. The federal pathway, if and when an FDA approval lands, would be the most likely trigger for Vermont to move, since the state has steered toward a provider-administered therapeutic model rather than decriminalization. Until then Vermont has little direct federal exposure here because it has authorized nothing for federal law to conflict with. (https://legislature.vermont.gov/assets/Legislative-Reports/The-Psychedelic-Therapy-Advisory-Working-Group_Final-Report.pdf)

Harm reduction. This is Vermont's sharpest federal exposure. Vermont runs comparatively strong programs (syringe services, broad naloxone, fentanyl and xylazine test strips) and is the rare state that statutorily authorized overdose prevention centers, with a Burlington site in development using opioid-settlement funds. The SAMHSA guidance of April 24, 2026 bars federal funds for fentanyl test strips, clean syringes, and sterile water; naloxone is still supported. That directly hits Vermont's syringe services and test-strip distribution, which lean on federal dollars, forcing the state to backfill from settlement funds or the general fund or scale back. The overdose prevention centers face a second, sharper layer of risk: supervised-consumption sites have no federal authorization and sit in direct tension with the federal "crack house" statute (21 U.S.C. 856), so a Republican DOJ could pursue federal legal action against the Burlington site regardless of state authorization. The HALT Fentanyl Act (July 17, 2025) permanently placed fentanyl-related substances in Schedule I, which raises penalties on the supply side without affecting Vermont's demand-side harm-reduction authority, but it signals the enforcement posture the OPC would operate under. (https://www.healthvermont.gov/sites/default/files/document/dsu-overdose-prevention-centers.pdf, https://vtdigger.org/2024/05/07/final-reading-lawmakers-send-safe-injection-site-pilot-legislation-to-gov-phil-scott/, https://www.vermontpublic.org/show/vermont-edition/2025-03-10/what-we-know-so-far-about-burlingtons-overdose-prevention-center-plans)

Patient access and rights

This section covers what Vermont law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026.

Hospital access (Ryan's Law): Vermont has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Vermont is not among them. The absence is the finding: a Vermont patient has no enforceable right to use their medicine in a hospital today.

Broader protections: Vermont has both a medical program and legal adult-use (it legalized through the legislature in 2018), but a review of the cannabis statutes, now recodified to Title 7, Chapter 35, found none of the six patient protections: no employment protection, and nothing for housing, parenting (reviewed 7 V.S.A. 953), an organ transplant list, school enrollment, or general medical care (no recodified medical-care clause at 7 V.S.A. 952). The absence is the finding.

Out-of-state patients: Vermont recognizes its own residents only; its adult-use market serves anyone 21 and older, but an out-of-state medical card carries no patient protections here.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Vermont has not enacted a Ryan's Law. The absence of the broader protections above is a feature of Vermont law, not something federal rescheduling addresses.

Sources: Vermont cannabis law, 7 V.S.A. Chapter 35.

Related reading from Drug Policy Watch: the Federal Drug Policy Brief, the Schedule III rescheduling explainer, and the 50-State Matrix.

Analysis: the enclosure read in depth

Who is fenced out and who consolidates. On its own terms, Vermont is one of the least enclosed cannabis regimes in the country. The license structure intentionally favors small and outdoor cultivators with low Tier 1 entry fees, the largest Tier 4 and Tier 5 licenses are paused to shield smaller growers from oversupply, social-equity priority and fee waivers are built in, expungement was automatic for the most common low-level offenses, and home grow is legal. By state design, very few small operators are fenced out, and there is no in-state structural pressure toward a few dominant incumbents. That is why the enclosure score is low.

State-plus-federal interaction. The squeeze comes almost entirely from the federal side, and it bites the very operators Vermont protects. The federal medicalize-and-control read favors large incumbents and FDA-track players: Schedule III relief for medical cannabis and the 280E exemption it brings reward scale and vertical integration, while Vermont's adult-use Tier 1 growers stay under full 280E and Schedule I. Stalled SAFER Banking compounds it, because cash-only operation, premium banking fees, and the absence of normal lending are survivable for a multistate operator and potentially fatal for a craft grower or social-equity licensee. So the paradox of Vermont is that the state built an anti-consolidation market, but the federal tax and banking levers it cannot control push toward exactly the consolidation it designed against. The hemp cliff is a smaller, mostly reinforcing factor, since Vermont already closed the intoxicating-hemp channel; its only sharp edge is the low-dose consumable-hemp lane that now exceeds the federal per-container cap. On harm reduction the interaction is starkest: Vermont has gone furthest in the country (authorized overdose prevention centers), so it has the most to lose from SAMHSA defunding and the most direct federal legal exposure under the crack-house statute.

What to watch. Whether the DEA rescheduling process produces anything beyond the narrow medical Schedule III move, and whether it slips to 2027. Whether the Burlington overdose prevention center opens and whether a Republican DOJ moves against it. How Vermont backfills SAMHSA-cut harm-reduction funding. Whether the 2025 low-dose consumable-hemp lane is amended to reconcile with the November 12, 2026 federal cap. And whether banking and 280E pressure begin to thin out the Tier 1 and social-equity cohort despite the state's protections.

Where the commons counter-moves are strongest. Vermont's most durable defenses against enclosure are home-grown and largely insulated from federal levers: the small-grower tiered licensing with the Tier 4 and Tier 5 pause, automatic expungement and social-equity priority, and a robust harm-reduction infrastructure including the statutorily authorized overdose prevention centers. The first two are state-law structures that federal rescheduling and banking gaps cannot directly repeal, even if they raise the cost of operating inside them. Harm reduction is the strongest commons move in spirit but the most federally exposed in practice, which is the central tension of this brief.

Why the score is 2/5. The state's own architecture is close to open, which on a state-only read would justify a 1. The score is held at 2, not lower, because the federal tax, banking, and harm-reduction levers actively press against Vermont's small-operator and harm-reduction commons in ways the state cannot fully neutralize. It is not higher because Vermont has no in-state consolidation engine: no ballot-initiative capture, deliberately capped large tiers, built-in equity and expungement, and an intoxicating-hemp channel already closed rather than handed to incumbents. The pressure is real but external and indirect, so 2/5 stands.

Enclosure pressure score: 2/5.

Active legislation (2026)

This list is not exhaustive. For the full set of bills and live status, see the Vermont General Assembly bill tracker (https://legislature.vermont.gov/), LegiScan Vermont (https://legiscan.com/VT).

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

  • Hemp regulation (Senate Agriculture) Further regulation of consumable/intoxicating hemp; CCB testimony Jan 8, 2026 (Committee work in progress; specific bill number unconfirmed)
  • Psychedelics follow-on (post-working-group) Possible therapeutic-access or decriminalization measure (Unconfirmed (no 2026 bill confirmed in this research))
  • Drug decriminalization (successor to H.423/S.119/S.300) All-drug personal-use decriminalization (Unconfirmed for 2026; prior sponsors Reps. Nicoll, Small; Sen. Vyhovsky)
Bill Title/Topic Chamber Status Sponsor(s)
S.278 Cannabis: raise possession limit to 2 oz, remove THC potency caps, cut excise tax 14% to 10%, authorize delivery and cannabis events Senate (origin), in House Passed Senate, sent to House Apr 1, 2026; House stripped potency-cap removal, tax cut, and delivery. Update, July 18, 2026: S.278 was signed into law, with provisions effective July 1, 2026 including the 2-ounce possession limit, interstate-commerce agreements, and a cannabis-events pilot. (source) Sen. Kesha Ram Hinsdale
H.321 Cannabis establishment fee schedule (referenced in 2026 committee work) House In committee / under review (status unconfirmed) Unconfirmed
Hemp regulation (Senate Agriculture) Further regulation of consumable/intoxicating hemp; CCB testimony Jan 8, 2026 Senate Committee work in progress; specific bill number unconfirmed Unconfirmed
Psychedelics follow-on (post-working-group) Possible therapeutic-access or decriminalization measure Unconfirmed Unconfirmed (no 2026 bill confirmed in this research) Unconfirmed
Drug decriminalization (successor to H.423/S.119/S.300) All-drug personal-use decriminalization Unconfirmed Unconfirmed for 2026; prior sponsors Reps. Nicoll, Small; Sen. Vyhovsky Unconfirmed
Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →

Sources